TY - JOUR
AU1 - Bechdolf, Andreas
AU2 - Müller, Hendrik
AU3 - Hellmich, Martin
AU4 - de Millas, Walter
AU5 - Falkai, Peter
AU6 - Gaebel, Wolfgang
AU7 - Gallinat, Jürgen
AU8 - Hasan, Alkomiet
AU9 - Heinz, Andreas
AU1 - Janssen, Birgit
AU1 - Juckel, Georg
AU1 - Karow, Anne
AU1 - Krüger-Özgürdal, Seza
AU1 - Lambert, Martin
AU1 - Maier, Wolfgang
AU1 - Meyer-Lindenberg, Andreas
AU1 - Pützfeld, Verena
AU1 - Rausch, Franziska
AU1 - Schneider, Frank
AU2 - Stützer, Hartmut
AU2 - Wobrock, Thomas
AU2 - Wagner, Michael
AU2 - Zink, Mathias
AU2 - Klosterkötter, Joachim
AB - BackgroundThere is limited knowledge of whether cognitive-behavioral therapy (CBT) or second-generation antipsychotics (SGAs) should be recommended as the first-line treatment in individuals at clinical high risk for psychosis (CHRp). HypothesisTo examine whether individual treatment arms are superior to placebo and whether CBT is non-inferior to SGAs in preventing psychosis over 12 months of treatment. Study DesignPREVENT was a blinded, 3-armed, randomized controlled trial comparing CBT to clinical management plus aripiprazole (CM + ARI) or plus placebo (CM + PLC) at 11 CHRp services. The primary outcome was transition to psychosis at 12 months. Analyses were by intention-to-treat. Study ResultsTwo hundred eighty CHRp individuals were randomized: 129 in CBT, 96 in CM + ARI, and 55 in CM + PLC. In week 52, 21 patients in CBT, 19 in CM + ARI, and 7 in CM + PLC had transitioned to psychosis, with no significant differences between treatment arms (P = .342). Psychopathology and psychosocial functioning levels improved in all treatment arms, with no significant differences. ConclusionsThe analysis of the primary outcome transition to psychosis at 12 months and secondary outcomes symptoms and functioning did not demonstrate significant advantages of the active treatments over placebo. The conclusion is that within this trial, neither low-dose aripiprazole nor CBT offered additional benefits over clinical management and placebo.
TI - Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT)
JF - Schizophrenia Bulletin
DO - 10.1093/schbul/sbad029
DA - 2023-04-06
UR - https://www.deepdyve.com/lp/oxford-university-press/prevention-of-first-episode-psychosis-in-people-at-clinical-high-risk-MFwLr6b0WT
SP - 1055
EP - 1066
VL - 49
IS - 4
DP - DeepDyve
ER -